SOLENO
PharmaSOLENO is a pharmaceutical company focused on Metabolic. Key products include VYKAT XR.
SOLENO's Key Drugs
SOLENO's core commercial portfolio centers on VYKAT XR, spanning Metabolic — its most strategically important drugs approved in the last 15 years.
SOLENO's Recent FDA Approvals
SOLENO secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
SOLENO's Therapeutic Areas
SOLENO's approved drugs and pipeline span 1 therapeutic area, led by Metabolic, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SOLENO's Top Competitors
SOLENO's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SOLENO Pipeline Snapshot
SOLENO has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 0 Phase 1.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • VYKAT XR leads revenue
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2025-03-26
- Latest
- 2025-03-26
- Applications
- 1